{"id":"W4407480694","doi":"10.1038/s41591-025-03581-2","title":"Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","year":2025,"lang":"en","type":"erratum","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency; Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Daratumumab; Lenalidomide; Dexamethasone; Bortezomib; Medicine; Multiple myeloma; Internal medicine; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009319218,0.002218012,0.00228263,0.00284536,0.002802167,0.004621939,0.003550474,0.007775439,0.03388857],"category_scores_gemma":[0.09488317,0.001436826,0.002040424,0.002306399,0.001855905,0.001912112,0.001411554,0.01647544,0.0180438],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004200357,"about_ca_system_score_gemma":0.008927313,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01298612,"about_ca_topic_score_gemma":0.01632092,"domain_scores_codex":[0.9928093,0.001640831,0.001362385,0.001067888,0.002589889,0.0005297103],"domain_scores_gemma":[0.9587191,0.01587062,0.002538183,0.001846148,0.01893888,0.002087014],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004256697,0.000004436036,0.0000306255,0.00006782749,0.00001204683,0.00008435625,0.000008775072,0.00001888604,0.00001134758,0.0003051121,0.9971366,0.002277327],"study_design_scores_gemma":[0.0003966214,0.00004757326,0.0006330851,0.0009186511,0.0001842966,0.000735908,0.00006585684,0.0003667134,0.0003997921,0.002327701,0.9938626,0.00006120966],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.00007507305,0.0008051944,0.0003720189,0.06507051,0.931616,0.00002686633,0.0006731453,0.0001553449,0.001205848],"genre_scores_gemma":[0.009085784,0.008217881,0.004477921,0.2589166,0.6063799,0.0003912035,0.002269241,0.001307295,0.1089542],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.03388857,"threshold_uncertainty_score":0.1133686,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03630016595111352,"score_gpt":0.3699775401689008,"score_spread":0.3336773742177873,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}